Flashbacks from the Past: Unraveling the Mystery of Hallucinogen Persisting Perception Disorder (HPPD)

Amir Mohammad Mottaghi
Post on 04 Sept 2025 . 2 min read.
Amir Mohammad Mottaghi
Post on 04 Sept 2025 . 2 min read.
The hallmark symptoms of HPPD include a range of visual disturbances, such as:
Afterimages: Persistent visual echoes of objects after they are no longer in view.
Visual snow or illusory movements: Perception of motion in the visual field where none exists.
Flashes or halos: Brief bursts of light or glowing outlines around objects.
Geometric patterns and unusual colors: Seeing shapes or vivid hues not present in reality.
Distorted object size or movement: Objects appearing to change size (micropsia/macropsia) or move unnaturally.
Trailing phenomena: Visual trails following moving objects.
Depersonalization/derealization: A sense of unreality or detachment from the environment.
These symptoms can provoke significant anxiety, fear, or social embarrassment, impacting daily functioning (Halpern & Pope, 2003).[3] The intensity and frequency of flashbacks vary widely among individuals, with some experiencing fleeting episodes and others enduring persistent visual disruptions.
HPPD is diagnosed based on criteria outlined in the DSM-5-TR, which include:
Re-experiencing perceptual symptoms resembling those of prior hallucinogen use.
Significant distress or impairment in social, occupational, or other areas of functioning.
Awareness that the symptoms are linked to prior drug use, distinguishing HPPD from other psychiatric conditions like schizophrenia (American Psychiatric Association, 2022)[2]
The condition is typically associated with prior use of hallucinogens, though even a single exposure to substances like LSD, PCP, MDMA, or cannabis can trigger it (Lerner et al., 2014). [6]
HPPD is categorized into two types:
Type 1: Brief, intermittent flashbacks that are generally less disruptive.
Type 2: Persistent, intrusive visual changes that significantly affect quality of life (Halpern et al., 2016). [4]
While the precise etiology of HPPD remains unclear, triggers such as stress, fatigue, anxiety, or substance use (e.g., caffeine or alcohol) may exacerbate symptoms. Neurobiological theories suggest that HPPD may result from persistent alterations in serotonin (5-HT2A) receptor activity or neural hyperexcitability in visual processing pathways (Abraham & Aldridge, 1993). [1]
No standardized treatment protocol exists for HPPD, but symptoms often diminish over time with abstinence from hallucinogens. Management strategies include:
Psychotherapy: Cognitive-behavioral therapy (CBT) and supportive counseling can help reduce anxiety and improve coping mechanisms (Lerner et al., 2002).[6]
Pharmacotherapy: In severe cases, medications such as clonazepam, lamotrigine, or low-dose atypical antipsychotics (e.g., risperidone) have been used experimentally, though evidence is limited (Hermle et al., 2012). [5]
Non-pharmacological approaches, including mindfulness, relaxation techniques, deep breathing exercises, and trigger identification, can help mitigate symptom severity. Support from mental health professionals or peer groups is also beneficial (Halpern et al., 2016). [4]
HPPD represents a rare but distressing consequence of hallucinogen use, characterized by persistent or recurrent perceptual disturbances. While its mechanisms are not fully understood, effective management relies on a combination of abstinence, psychological support, and, in some cases, pharmacological intervention. Ongoing research is necessary to better elucidate its pathophysiology and optimize treatment strategies.
© All copyright of this material is absolute to Medical toxicology
Tarbiat Modares University employs a clinical toxicologist with a Master of Toxicology and expertise in toxins and clinical toxicology. Previously, they completed a four-year program at mui.ac.ir, gaining foundational knowledge in their field. As part of their professional development, they earned multiple certifications in data science and programming, including Python and Jupyter, complementing their technical acumen. Proficient in English as a Second Language (ESL), they bring diverse skills to their role, supporting research and applied toxicology initiatives.
Abraham, H. D., & Aldridge, A. M. (1993). Adverse consequences of lysergic acid diethylamide. Addiction, 88(10), 1327–1334. https://doi.org/10.1111/j.1360-0443.1993.tb02018.x
American Psychiatric Association. (2022). Diagnostic and Statistical Manual of Mental Disorders (5th ed., text revision). American Psychiatric Publishing.
Halpern, J. H., & Pope, H. G. (2003). Hallucinogen persisting perception disorder: What do we know after 50 years? Drug and Alcohol Dependence, 69(2), 109–119. https://doi.org/10.1016/S0376-8716(02)00306-X
Halpern, J. H., Lerner, A. G., & Passie, T. (2016). A review of hallucinogen persisting perception disorder (HPPD) and an exploratory study of subjects claiming symptoms of HPPD. Current Topics in Behavioral Neurosciences, 36, 333–346. https://doi.org/10.1007/7854_2016_453
Hermle, L., Simon, M., Ruchsow, M., & Geppert, M. (2012). Hallucinogen persisting perception disorder. Therapeutic Advances in Psychopharmacology, 2(5), 199–205. https://doi.org/10.1177/2045125312451270
Lerner, A. G., Gelkopf, M., Oyffe, I., Finkel, B., Katz, S., Sigal, M., & Weizman, A. (2002). Clonazepam treatment of lysergic acid diethylamide-induced perceptual disorders. Journal of Clinical Psychiatry, 63(7), 577–579. https://doi.org/10.4088/JCP.v63n0704
Lerner, A. G., Rudinski, D., Bor, O., & Goodman, C. (2014). Flashbacks and HPPD: A clinical-oriented concise review. Israel Journal of Psychiatry and Related Sciences, 51(4), 296–301.